384 related articles for article (PubMed ID: 25661083)
1. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.
Sautto GA; Wisskirchen K; Clementi N; Castelli M; Diotti RA; Graf J; Clementi M; Burioni R; Protzer U; Mancini N
Gut; 2016 Mar; 65(3):512-23. PubMed ID: 25661083
[TBL] [Abstract][Full Text] [Related]
2. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.
Bohne F; Chmielewski M; Ebert G; Wiegmann K; Kürschner T; Schulze A; Urban S; Krönke M; Abken H; Protzer U
Gastroenterology; 2008 Jan; 134(1):239-47. PubMed ID: 18166356
[TBL] [Abstract][Full Text] [Related]
3. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
[TBL] [Abstract][Full Text] [Related]
7. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.
Ojiro K; Qu X; Cho H; Park JJ; Vuidepot A; Lissin N; Molloy PE; Bennett A; Jakobsen BK; Kaplan DE; Riley JL; Chang KM
J Virol; 2017 May; 91(10):. PubMed ID: 28275182
[TBL] [Abstract][Full Text] [Related]
9. Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.
Bhattarai N; McLinden JH; Xiang J; Kaufman TM; Stapleton JT
PLoS Pathog; 2015 Sep; 11(9):e1005183. PubMed ID: 26421924
[TBL] [Abstract][Full Text] [Related]
10. Synthesized peptides 705-734 from hepatitis C virus E2 glycoprotein induce dendritic cell maturation by activating p38 MAPK signaling.
Liu X; Chen N; Lin S; Liu M
Int Immunopharmacol; 2016 Jan; 30():194-201. PubMed ID: 26604090
[TBL] [Abstract][Full Text] [Related]
11. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
[TBL] [Abstract][Full Text] [Related]
12. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
[TBL] [Abstract][Full Text] [Related]
13. Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
Das S; Behera P; Shewale DJ; Bodele J; Das S; Karande AA
Arch Virol; 2024 Apr; 169(5):112. PubMed ID: 38683226
[TBL] [Abstract][Full Text] [Related]
14. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection.
Bain C; Parroche P; Lavergne JP; Duverger B; Vieux C; Dubois V; Komurian-Pradel F; Trépo C; Gebuhrer L; Paranhos-Baccala G; Penin F; Inchauspé G
J Virol; 2004 Oct; 78(19):10460-9. PubMed ID: 15367612
[TBL] [Abstract][Full Text] [Related]
15. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
Desombere I; Fafi-Kremer S; Van Houtte F; Pessaux P; Farhoudi A; Heydmann L; Verhoye L; Cole S; McKeating JA; Leroux-Roels G; Baumert TF; Patel AH; Meuleman P
Hepatology; 2016 Apr; 63(4):1120-34. PubMed ID: 26710081
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
18. Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.
Koh S; Kah J; Tham CYL; Yang N; Ceccarello E; Chia A; Chen M; Khakpoor A; Pavesi A; Tan AT; Dandri M; Bertoletti A
Gastroenterology; 2018 Jul; 155(1):180-193.e6. PubMed ID: 29550589
[TBL] [Abstract][Full Text] [Related]
19. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
20. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins.
Sarobe P; Lasarte JJ; García N; Civeira MP; Borrás-Cuesta F; Prieto J
J Viral Hepat; 2006 Jan; 13(1):47-55. PubMed ID: 16364082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
